Cargando…

Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Originf

The objective of this study is to analyze oncological outcomes of patients with peritoneal metastases (PM) of colorectal origin treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). BACKGROUND: PIPAC has been demonstrated to be a feasible and safe novel treatment for patients with P...

Descripción completa

Detalles Bibliográficos
Autores principales: Hübner, Martin, Somashekhar, S. P., Teixeira Farinha, Hugo, Abba, Julio, Rao, Ramya G., Alyami, Mohammad, Willaert, Wouter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406066/
https://www.ncbi.nlm.nih.gov/pubmed/37600288
http://dx.doi.org/10.1097/AS9.0000000000000203
_version_ 1785085668054007808
author Hübner, Martin
Somashekhar, S. P.
Teixeira Farinha, Hugo
Abba, Julio
Rao, Ramya G.
Alyami, Mohammad
Willaert, Wouter
author_facet Hübner, Martin
Somashekhar, S. P.
Teixeira Farinha, Hugo
Abba, Julio
Rao, Ramya G.
Alyami, Mohammad
Willaert, Wouter
author_sort Hübner, Martin
collection PubMed
description The objective of this study is to analyze oncological outcomes of patients with peritoneal metastases (PM) of colorectal origin treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). BACKGROUND: PIPAC has been demonstrated to be a feasible and safe novel treatment for patients with PM of various origins. Only small series reports on survival after PIPAC by disease entity. METHODS: International retrospective cohort study of consecutive patients with PM of colorectal origin. Outcome measures were overall survival (OS), radiological response according to Response Evaluation Criteria in Solid Tumors (RECIST), histological response (peritoneal regression grading score [PRGS]: complete response: 1–4: no response), change of peritoneal cancer index (PCI), and symptom control. RESULTS: Seventeen eligible centers compiled 256 non-selected patients (mean age 61 [50.6–69.2], 43% female) and 606 procedures. Sixty-three percent were treated after 2 lines of chemotherapy, median PCI at PIPAC1 was 18 (interquartile range [IQR] = 10–27). Median OS was 19.00 months (IQR = 12.9–29.8) from diagnosis and 9.4 months (IQR = 4.5–16.8) from PIPAC1. One hundred and four of 256 patients (40.6%) had ≥3 procedures (per protocol [pp]) with the following outcomes at PIPAC3: RECIST: 59.3% partial response/stable, 40.7% progression; mean PRGS: 2.1 ± 0.9. Median PCI was 21 (IQR = 15–29) at baseline and 20 (IQR = 12–27) at PIPAC3 (P = 0.02). Fifty-six (54%) and 48 (46%) patients were symptomatic at baseline and PIPAC3, respectively (P = 0.267). Median OS for the pp cohort was 11.9 months (IQR = 10.7–15.0) from PIPAC1. Independent predictors for survival were radiological response (HR = 3.0; 95% CI = 1.6–5.7) and no symptoms (HR = 4.5, 95% CI = 2.2–9.1) at PIPAC3. CONCLUSIONS: Objective treatment response and encouraging survival were demonstrated after PIPAC for colorectal PM. Prospective registry data and comparative studies are now needed in to confirm these data.
format Online
Article
Text
id pubmed-10406066
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer Health, Inc.
record_format MEDLINE/PubMed
spelling pubmed-104060662023-08-18 Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Originf Hübner, Martin Somashekhar, S. P. Teixeira Farinha, Hugo Abba, Julio Rao, Ramya G. Alyami, Mohammad Willaert, Wouter Ann Surg Open Original Study The objective of this study is to analyze oncological outcomes of patients with peritoneal metastases (PM) of colorectal origin treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). BACKGROUND: PIPAC has been demonstrated to be a feasible and safe novel treatment for patients with PM of various origins. Only small series reports on survival after PIPAC by disease entity. METHODS: International retrospective cohort study of consecutive patients with PM of colorectal origin. Outcome measures were overall survival (OS), radiological response according to Response Evaluation Criteria in Solid Tumors (RECIST), histological response (peritoneal regression grading score [PRGS]: complete response: 1–4: no response), change of peritoneal cancer index (PCI), and symptom control. RESULTS: Seventeen eligible centers compiled 256 non-selected patients (mean age 61 [50.6–69.2], 43% female) and 606 procedures. Sixty-three percent were treated after 2 lines of chemotherapy, median PCI at PIPAC1 was 18 (interquartile range [IQR] = 10–27). Median OS was 19.00 months (IQR = 12.9–29.8) from diagnosis and 9.4 months (IQR = 4.5–16.8) from PIPAC1. One hundred and four of 256 patients (40.6%) had ≥3 procedures (per protocol [pp]) with the following outcomes at PIPAC3: RECIST: 59.3% partial response/stable, 40.7% progression; mean PRGS: 2.1 ± 0.9. Median PCI was 21 (IQR = 15–29) at baseline and 20 (IQR = 12–27) at PIPAC3 (P = 0.02). Fifty-six (54%) and 48 (46%) patients were symptomatic at baseline and PIPAC3, respectively (P = 0.267). Median OS for the pp cohort was 11.9 months (IQR = 10.7–15.0) from PIPAC1. Independent predictors for survival were radiological response (HR = 3.0; 95% CI = 1.6–5.7) and no symptoms (HR = 4.5, 95% CI = 2.2–9.1) at PIPAC3. CONCLUSIONS: Objective treatment response and encouraging survival were demonstrated after PIPAC for colorectal PM. Prospective registry data and comparative studies are now needed in to confirm these data. Wolters Kluwer Health, Inc. 2022-10-24 /pmc/articles/PMC10406066/ /pubmed/37600288 http://dx.doi.org/10.1097/AS9.0000000000000203 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Study
Hübner, Martin
Somashekhar, S. P.
Teixeira Farinha, Hugo
Abba, Julio
Rao, Ramya G.
Alyami, Mohammad
Willaert, Wouter
Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Originf
title Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Originf
title_full Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Originf
title_fullStr Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Originf
title_full_unstemmed Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Originf
title_short Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Originf
title_sort treatment response after pressurized intraperitoneal aerosol chemotherapy (pipac) for peritoneal metastases of colorectal originf
topic Original Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406066/
https://www.ncbi.nlm.nih.gov/pubmed/37600288
http://dx.doi.org/10.1097/AS9.0000000000000203
work_keys_str_mv AT hubnermartin treatmentresponseafterpressurizedintraperitonealaerosolchemotherapypipacforperitonealmetastasesofcolorectaloriginf
AT somashekharsp treatmentresponseafterpressurizedintraperitonealaerosolchemotherapypipacforperitonealmetastasesofcolorectaloriginf
AT teixeirafarinhahugo treatmentresponseafterpressurizedintraperitonealaerosolchemotherapypipacforperitonealmetastasesofcolorectaloriginf
AT abbajulio treatmentresponseafterpressurizedintraperitonealaerosolchemotherapypipacforperitonealmetastasesofcolorectaloriginf
AT raoramyag treatmentresponseafterpressurizedintraperitonealaerosolchemotherapypipacforperitonealmetastasesofcolorectaloriginf
AT alyamimohammad treatmentresponseafterpressurizedintraperitonealaerosolchemotherapypipacforperitonealmetastasesofcolorectaloriginf
AT willaertwouter treatmentresponseafterpressurizedintraperitonealaerosolchemotherapypipacforperitonealmetastasesofcolorectaloriginf